CHARACTERIZATION OF B-CELL LINES ESTABLISHED FROM 2 X-LINKED SEVERE COMBINED IMMUNODEFICIENCY PATIENTS - INTERLEUKIN-15 BINDS TO THE B-CELLS BUT IS NOT INTERNALIZED EFFICIENTLY

被引:31
作者
KUMAKI, S
OCHS, HD
TIMOUR, M
SCHOOLEY, K
AHDIEH, M
HILL, H
SUGAMURA, K
ANDERSON, D
ZHU, QL
COSMAN, D
GIRI, JG
机构
[1] UNIV WASHINGTON, DEPT PEDIAT, SEATTLE, WA USA
[2] UNIV UTAH, DEPT PATHOL, SALT LAKE CITY, UT USA
[3] TOHOKU UNIV, SCH MED, DEPT MICROBIOL, SENDAI, MIYAGI 980, JAPAN
关键词
D O I
10.1182/blood.V86.4.1428.bloodjournal8641428
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
X-linked severe combined immunodeficiency (XSCID) is characterized by absent or profoundly reduced numbers of T cells and normal numbers of B cells in the circulation. Affected patients have mutations of the interleukin-2 (IL-2) receptor gamma chain gene. Using Epstein-Barr virus-transformed B-lymphoblastoid cell lines (B-LCLs) established from two unrelated XSCID patients, we could show that neither expressed the IL-2 receptor gamma chain on the cell surface. A novel cytokine IL-15, which has biologic activities similar to those of IL-2, could bind to the XSCID B-LCLs in the absence of the gamma chain, although both the beta and gamma chains of the human IL-2 receptor were previously shown to be required for IL-15 binding by transfected COS cells. Furthermore, a significant reduction and delay of IL-15 internalization by B lymphoblasts from XSCID patients was observed when compared with that of normal control B-LCLs. These results show the existence of a novel IL-15-specific receptor component that contributes to IL-15 binding but is insufficient for IL-15 internalization in the absence of the IL-2 receptor gamma chain. (C) 1995 by The American Society of Hematology.
引用
收藏
页码:1428 / 1436
页数:9
相关论文
共 25 条
[1]  
AMMANN AJ, 1989, IMMUNOLOGIC DISORDER, V3, P829
[2]  
ARMITAGE RJ, 1995, J IMMUNOL, V154, P483
[3]  
BUCKLEY RH, 1986, J IMMUNOL, V136, P2398
[4]   INTERLEUKIN (IL)-15 IS A NOVEL CYTOKINE THAT ACTIVATES HUMAN NATURAL-KILLER-CELLS VIA COMPONENTS OF THE IL-2 RECEPTOR [J].
CARSON, WE ;
GIRI, JG ;
LINDEMANN, MJ ;
LINETT, ML ;
AHDIEH, M ;
PAXTON, R ;
ANDERSON, D ;
EISENMANN, J ;
GRABSTEIN, K ;
CALIGIURI, MA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (04) :1395-1403
[5]  
CONLEY ME, 1992, ANNU REV IMMUNOL, V10, P215
[6]   X-LINKED SEVERE COMBINED IMMUNODEFICIENCY - DIAGNOSIS IN MALES WITH SPORADIC SEVERE COMBINED IMMUNODEFICIENCY AND CLARIFICATION OF CLINICAL FINDINGS [J].
CONLEY, ME ;
BUCKLEY, RH ;
HONG, R ;
GUERRAHANSON, C ;
ROIFMAN, CM ;
BROCHSTEIN, JA ;
PAHWA, S ;
PUCK, JM .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (05) :1548-1554
[7]  
DESAINTBASILE G, 1987, P NATL ACAD SCI USA, V84, P7576
[8]   INTERLEUKIN-2 (IL-2) RECEPTOR-GAMMA CHAIN MUTATIONS IN X-LINKED SEVERE COMBINED IMMUNODEFICIENCY DISEASE RESULT IN THE LOSS OF HIGH-AFFINITY IL-2 RECEPTOR-BINDING [J].
DISANTO, JP ;
DAUTRYVARSAT, A ;
CERTAIN, S ;
FISCHER, A ;
DESAINTBASILE, G .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (02) :475-479
[9]  
Gelfand E W, 1983, Birth Defects Orig Artic Ser, V19, P65
[10]   UTILIZATION OF THE BETA-CHAIN AND GAMMA-CHAIN OF THE IL-2 RECEPTOR BY THE NOVEL CYTOKINE-IL-15 [J].
GIRI, JG ;
AHDIEH, M ;
EISENMAN, J ;
SHANEBECK, K ;
GRABSTEIN, K ;
KUMAKI, S ;
NAMEN, A ;
PARK, LS ;
COSMAN, D ;
ANDERSON, D .
EMBO JOURNAL, 1994, 13 (12) :2822-2830